Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2~* Must have recovered from all side effects of their most recent systemic or local treatment~* Adequate hematological, renal and liver function~For solid tumors only:~* Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation and that are resistant to standard therapy or for which standard or curative therapy does not exist~* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)~For multiple myeloma only:~* Confirmed diagnosis of multiple myeloma with a BRAF V600 mutation~* Must have received at least one prior systemic therapy for the treatment of multiple myeloma~* Treated with local radiotherapy~* Must have relapsed and/or refractory multiple myeloma with measurable disease~Exclusion Criteria:~* Melanoma, papillary thyroid cancer or hematological malignancies (with the exception of multiple myeloma)~* Uncontrolled concurrent malignancy~* Multiple myeloma: solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia~* Active or untreated central nervous system (CNS) metastases~* History of or known carcinomatous meningitis~* Concurrent administration of any anti-cancer therapies other than those administered in this study~* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that would, in the investigator's opinion, contraindicate participation in this study

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib (Type: EXPERIMENTAL): Participants with NSCLC will be treated with vemurafenib monotherapy.
- Cohort 2: Ovarian Cancer - vemurafenib (Type: EXPERIMENTAL): Participants with ovarian cancer will be treated with vemurafenib monotherapy.
- Cohort 3a: Colorectal Cancer - vemurafenib (Type: EXPERIMENTAL): Participants with colorectal cancer will be treated with vemurafenib monotherapy.
- Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab (Type: EXPERIMENTAL): Participants with colorectal cancer will be treated with vemurafenib and cetuximab combination therapy.
- Cohort 4: Cholangiocarcinoma - vemurafenib (Type: EXPERIMENTAL): Participants with cholangiocarcinoma will be treated with vemurafenib monotherapy.
- Cohort 6: Multiple Myeloma - vemurafenib (Type: EXPERIMENTAL): Participants with multiple myeloma will be treated with vemurafenib monotherapy.
- Cohort 7: Other Solid Tumors - vemurafenib (Type: EXPERIMENTAL): Participants with Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), anaplastic thyroid cancer, advanced stage astrocytoma, early stage astrocytoma and other BRAF V600-positive tumors will be treated with vemurafenib monotherapy. Subcohorts will be analyzed separately if 7 or more participants are enrolled for each indication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete